Family matters: How MYC family oncogenes impact small cell lung cancer.

Journal Article (Journal Article;Review)

Small cell lung cancer (SCLC) is one of the most deadly cancers and currently lacks effective targeted treatment options. Recent advances in the molecular characterization of SCLC has provided novel insight into the biology of this disease and raises hope for a paradigm shift in the treatment of SCLC. We and others have identified activation of MYC as a driver of susceptibility to Aurora kinase inhibition in SCLC cells and tumors that translates into a therapeutic option for the targeted treatment of MYC-driven SCLC. While MYC shares major features with its paralogs MYCN and MYCL, the sensitivity to Aurora kinase inhibitors is unique for MYC-driven SCLC. In this review, we will compare the distinct molecular features of the 3 MYC family members and address the potential implications for targeted therapy of SCLC.

Full Text

Duke Authors

Cited Authors

  • Brägelmann, J; Böhm, S; Guthrie, MR; Mollaoglu, G; Oliver, TG; Sos, ML

Published Date

  • August 18, 2017

Published In

Volume / Issue

  • 16 / 16

Start / End Page

  • 1489 - 1498

PubMed ID

  • 28737478

Pubmed Central ID

  • PMC5584863

Electronic International Standard Serial Number (EISSN)

  • 1551-4005

Digital Object Identifier (DOI)

  • 10.1080/15384101.2017.1339849


  • eng

Conference Location

  • United States